Anti-cancer fusion polypeptide capable of binding both CD137 and glypican-3 (GPC3)

US11919931B2 · kind B2 · utility

Assignee

• Pieris Pharmaceuticals GmbH · DE

Inventors

• Marlon Hinner · Freising, DE
• Rachida Siham Bel Aiba · Munich, DE
• Christine Rothe · Freising, DE
• Shane Olwill · Freising, DE
• Corinna Schlosser · Freising, DE

Key dates

• Filing date: Feb 5, 2021
• Grant date: Mar 5, 2024
• Expiry date: Jun 21, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/33
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The disclosure provides a fusion polypeptide specific for both CD137 and GPC3, which fusion polypeptide can be useful for directing CD137 clustering and activation to GPC3-positive tumor cells. Such fusion polypeptide can be used in many pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as a variety of tumors. The present disclosure also concerns methods of making the fusion polypeptide described herein as well as compositions comprising such fusion polypeptide. The present disclosure further relates to nucleic acid molecules encoding such fusion polypeptide and to methods for generation of such fusion polypeptide and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of such fusion polypeptide as well as compositions comprising one or more of such fusion polypeptides.